() CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver on Skype from Toronto to share news the company has signed an agreement with the British Columbia based Premier Health Group to use the industry’s only medical cannabis-specific Clinical Decision Support tool.
This deal gives CB2 access to 4600 physicians and data gathered from over 300 thousand patients.
CSE:CBII
Market: CSE
Market Cap: $9.6 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Full interview: CB2 Insights announces key partnership with GL Brands for...
CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...
on 12/17/2019
2 min read
Prev article
2 min read